*2.2.2.3 Preliminary results presented at the Connective Tissue Oncology Society meetings, November, 2020*

The overall response rate reported was 13.3% (95% CI: 3.8% to 30.7%) and the median PFS was 7.2 months (95% CI: 5.3 to 9.0 months). No complete responses occurred although four patients achieved a partial response and the majority of patients achieved stable disease. Seven patients from part 1 and six patients from part 2 experienced ≥ grade 3 treatment emergent adverse events including fatigue (10.0%), hypertension (10.0%), nausea (10.0%), anemia (16.7%) and asthenia (10.0%). Two patients experienced fatal adverse events, although there were no noted treatment related deaths. Nine patients eventually discontinued the study due to toxicity, and nine patients also received a dose reduction. No unexpected side effects were noted as a result of the combined treatment.
